Medtronic’s Micra Transcatheter Pacemaker shows promise in new study

Medtronic has announced new clinical trial data demonstrating the early benefits demonstrated by its Micra Transcatheter Pacemaker System (TPS).

Findings from the Medtronic Micra TPS Global Clinical Trial have shown that the miniaturised pacemaker has met its initial safety and performance measures, in the largest report to date of a transcatheter pacing system.

It was revealed that 100 percent of the first 140 patients who received the Micra TPS experienced a successful implant procedure, with mean electrical pacing measurements at all patient visits within expected ranges.

Dr Philippe Ritter, principal investigator of the Micra TPS Global Clinical Trial and cardiologist at University Hospital of Bordeaux, said: "This transcatheter pacing therapy will prove to be an effective but simpler and less-invasive pacemaker option for many patients."

The device is revolutionary in a number of ways, being comparable in size to a large vitamin and going beyond the need to use of wires to deliver pacing therapy.

It received European CE Mark approval last month based on the positive findings of this clinical trial.